Literature DB >> 22082521

Hypercoagulable states.

Julia A M Anderson1, Jeffrey I Weitz.   

Abstract

Hypercoagulable states can be inherited or acquired. Inherited hypercoagulable states can be caused by a loss of function of natural anticoagulant pathways or a gain of function in procoagulant pathways. Acquired hypercoagulable risk factors include a prior history of thrombosis, obesity, pregnancy, cancer and its treatment, antiphospholipid antibody syndrome, heparin-induced thrombocytopenia, and myeloproliferative disorders. Inherited hypercoagulable states combine with acquired risk factors to establish the intrinsic risk of venous thromboembolism for each individual. Venous thromboembolism occurs when the risk exceeds a critical threshold. Often a triggering factor, such as surgery, pregnancy, or estrogen therapy, is required to increase the risk above this critical threshold.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082521     DOI: 10.1016/j.ccc.2011.09.007

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  10 in total

1.  Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T.

Authors:  Matthew B Bloom; Jeffrey Johnson; Oksana Volod; Ernest Y Lee; Terris White; Daniel R Margulies
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

Review 2.  Prethrombotic, prothrombotic, thrombophilic states, hypercoagulable state, thrombophilia etc.: semantics should be respected even in medical papers.

Authors:  A Girolami; E Cosi; S Ferrari; A M Lombardi; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

3.  Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity.

Authors:  Silvio Buscemi; Davide Corleo; Cristiana Randazzo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Blood Stasis Syndrome Accelerates the Growth and Metastasis of Breast Cancer by Promoting Hypoxia and Immunosuppressive Microenvironment in Mice.

Authors:  Lu Jin; Biqiang Tang; Xia Liu; Weiye Mao; Linying Xia; Yueguang Du; Bing Ji; Qiyang Shou; Huiying Fu
Journal:  J Immunol Res       Date:  2022-06-07       Impact factor: 4.493

Review 5.  Inherited, congenital and acquired disorders by hemostasis (vascular, platelet & plasmatic phases) with repercussions in the therapeutic oral sphere.

Authors:  Juan-José Arrieta-Blanco; Ricardo Oñate-Sánchez; Federico Martínez-López; Daniel Oñate-Cabrerizo; Maria-del Carmen Cabrerizo-Merino
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-05-01

6.  Study on the Effect of Ginsenosides Rb on Blood of Tumor Mice.

Authors:  Mengmeng Zheng; Wenxiu Zheng; Wei Wang; Hong Guo; Hui Cao; Xiaowei Cui; Shanshan Wang; Chunchao Han
Journal:  Biomed Res Int       Date:  2019-08-18       Impact factor: 3.411

7.  [Thromboembolic manifestations in 36 HIV-infected patients in West Africa].

Authors:  Frédéric Nogbou Ello; Lidaw Déassoua Bawe; Gisèle Affoué Kouakou; Chrysostome Melaine Mossou; Doumbia Adama; Alain N'douba Kassi; Dine Mourtada; Eboi Ehui; Aristophane Tanon; Christophe Konin; François Eba Aoussi; Aka Rigobert Kakou; Serge Paul Eholié
Journal:  Pan Afr Med J       Date:  2018-12-06

8.  Risk Factors in Hospitalized Patients for Heparin-Induced Thrombocytopenia by Real World Database: A New Role for Primary Hypercoagulable States.

Authors:  Jasmeet Kaur; Camelia Arsene; Sumeet Kumar Yadav; Olusola Ogundipe; Ambreen Malik; Anupam Ashutosh Sule; Geetha Krishnamoorthy
Journal:  J Hematol       Date:  2020-08-04

9.  Concordance between clinical diagnosis of pulmonary thromboembolism at hospital discharge and anatomopathological diagnosis.

Authors:  Benjamín Rubio-Jurado; Rocío Concepción Albores-Arguijo; Antonio Guerra-Soto; Teresita Plasencia-Ortiz; Gerónimo Tavarez-Macías; Jennifer Huerta-Hernández; Carlos Riebeling-Navarro; Arnulfo Hernán Nava-Zavala
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

10.  Huisheng Oral Solution exerts anti-tumor effects by downregulating tissue factor and inhibiting the expression of metastasis-related factors, CD44, MMP2, and VEGF.

Authors:  Zhonghua Chen; Mei Liu; Kaiyong Xie; Haitao Chen; Jun Wang; Xing Liu
Journal:  Transl Cancer Res       Date:  2019-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.